What is maturity‑onset diabetes of the young (MODY)?

What is MODY (Maturity-Onset Diabetes of the Young)?

MODY is a monogenic form of diabetes inherited in an autosomal dominant pattern, characterized by early-onset hyperglycemia (classically before age 25 years) due to impaired insulin secretion with minimal or no defects in insulin action, caused by mutations in at least 13 different genes. 1

Key Defining Features

MODY differs fundamentally from Type 1 and Type 2 diabetes:

• Inheritance pattern: Autosomal dominant—meaning a 50% chance of transmission to offspring 2
• Age of onset: Typically presents in adolescence or young adulthood, though diagnosis can occur at older ages 2
• Pathophysiology: Primary defect is in insulin secretion, not insulin resistance (unless obesity coexists) 2
• Absence of autoimmunity: No pancreatic islet autoantibodies characteristic of Type 1 diabetes 1

Most Common MODY Subtypes

The three most frequently encountered forms account for approximately 80% of all MODY cases:

GCK-MODY (MODY 2)

• Caused by glucokinase gene mutations
• Clinical presentation: Mild, stable, nonprogressive fasting hyperglycemia present from birth
• Natural history: Microvascular complications are rare; small rise in 2-hour glucose on OGTT (<54 mg/dL)
• Treatment: Typically requires no pharmacological therapy except during pregnancy 1, 2

HNF1A-MODY (MODY 3)

• Most common form of MODY
• Clinical presentation: Progressive insulin secretory defect presenting in adolescence or early adulthood
• Distinctive features: Lowered renal threshold for glucosuria; large rise in 2-hour glucose on OGTT (>90 mg/dL)
• Treatment: Highly sensitive to low-dose sulfonylureas as first-line therapy; insulin may be needed over time 1, 2

HNF4A-MODY (MODY 1)

• Clinical presentation: Progressive insulin secretory defect similar to HNF1A-MODY
• Distinctive features: May present with large birth weight and transient neonatal hypoglycemia
• Treatment: Sensitive to sulfonylureas as first-line therapy 1, 2

Less Common but Clinically Important Subtypes

HNF1B-MODY (MODY 5)

• Associated with renal cysts and diabetes (RCAD) syndrome
• Features: Developmental renal disease (typically cystic), genitourinary abnormalities, pancreatic atrophy, hyperuricemia, and gout 2

Critical Clinical Implications

Why Accurate Diagnosis Matters for Patient Outcomes

Genetic diagnosis fundamentally changes management and improves quality of life:

1. GCK-MODY patients can avoid unnecessary lifelong treatment and the burden of medication side effects 1

2. HNF1A/HNF4A-MODY patients can transition from insulin to low-dose sulfonylureas, achieving better glycemic control with simpler regimens 1, 3

3. Family screening becomes possible—asymptomatic relatives can receive predictive genetic testing and early intervention 2

4. Prevention of complications through appropriate, genotype-specific treatment 4

When to Suspect MODY

Consider MODY in patients with:

• Diabetes diagnosed before age 25 years
• Strong family history of diabetes across multiple generations (autosomal dominant pattern)
• Diabetes not characteristic of Type 1 (no autoantibodies, preserved C-peptide) or Type 2 (lean, young, no insulin resistance features)
• Mild, stable hyperglycemia that doesn't progress as expected 1, 2

Important caveat: The presence of autoantibodies typically suggests Type 1 diabetes, but autoantibodies have been reported in some individuals with monogenic diabetes, so their presence doesn't absolutely exclude MODY 1

Diagnostic Approach

Genetic testing is warranted when MODY is suspected based on clinical features 1. Next-generation sequencing panels are increasingly available and cost-effective 1.

Consultation with a center specializing in diabetes genetics is recommended to:

• Interpret the significance of genetic mutations
• Guide further evaluation and treatment
• Provide comprehensive genetic counseling regarding inheritance patterns and cardiovascular risk 1

Treatment Paradigm Based on Genotype

The treatment approach is genotype-specific and represents true precision medicine:

• GCK-MODY: No treatment (except pregnancy) 1, 2
• HNF1A-MODY and HNF4A-MODY: Sulfonylureas first-line; insulin if needed later 1, 2, 3
• HNF1B-MODY and INS-MODY: Insulin remains mainstay 3

Recent evidence suggests emerging roles for newer agents (SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors) in selected MODY subtypes, though this remains largely exploratory based on small studies 3, 5. The established genotype-guided recommendations remain the standard of care.